published 1,2 regarding leukemia relapse after BMT which summarize strategies for prevention and treatment of leukemia relapse after BMT. In these articles, treatment for leuTo assess the consequence of second BMT (BMT2) for leukemia relapse after allogeneic BMT, we analyzed the kemia relapse was analyzed in four parts; reinduction chemoradiotherapy, cytokine therapy, donor leukocyte clinical course of 66 recipients who were treated by BMT2 in Japan. Diagnoses included 29 ANLL, 27 ALL, transfusion, and second allogeneic BMT (BMT2). The rate of achieving complete remission by reinduction chemosix CML and four MDS. Durations between the first BMT (BMT1) to relapse and BMT1 to BMT2 were therapy ranged from 30 to 50% in acute leukemias and the median duration of remission was very short, between 6 13.5 ± ± ± 13.7 months and 17.4 ± ± ± 13.9 months, respectively. Donors for BMT2 were replaced in 11 cases. Thirty-one and 14 months. 3 The response to interferon-␣ and donor leukocyte transfusion was good only for chronic phase patients were in CR (or CP) at BMT2. Earlier deaths were observed in those who received BMT2 within 12 CML and poor during the acute phase of CML and acute leukemia. 4 Therefore, BMT2 may be the only hopeful treatmonths after BMT1, mostly caused by regimen-related toxicity and infections. Overall leukemia-free survival ment for leukemia relapsing after BMT. There are many reports 5-8 concerning BMT2 which show rate was 28% at 2 years and 16% at 4 years. Factors influencing the poor prognosis after BMT2 were early 8-76% disease-free survival depending on the diagnosis, disease status, and many other factors which may affect (Ͻ6 months) relapse, early (Ͻ12 months) BMT2, not in remission at BMT2, and ALL. Intensified conditioning
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row donors for BMT1 were 58 siblings, four syngeneic with the institutes and patients. We analyzed cases by the number of high-dose chemoradiotherapies they had twins, one parent and three relatives. T cell depletion was not performed in any case. Bone marrow relapse occurred received. Criteria for high-dose regimens were у120 mg/kg CY, у10 Gy TBI, у16 mg/kg BU, у200 mg/kg or in 63 patients and four of these also had extramedullary leukemia (femur tumor, skull tumor, testis tumor and men-у12 g/m 2 Ara-C, у40 mg/kg or у1.6 g/m 2 etoposide (Eto), and у2.5 mg/kg or у140 mg/m 2 melphalan (Mel). Prophyingeal leukemia). The other three patients showed isolated extramedullary leukemia (skull tumor, knee joint leukemic laxis for GVHD was cyclosporin A (CsA) in 17 cases, CsA and short MTX in 23 cases, MTX in 12 cases, and seven arthritis and meningeal leukemia). Fifty-four patients received induction chemotherapy which resulted in 30 others. Four syngeneic and five sibling transplants were performed without GVHD prophylaxis. remissions. Radiation therapy was administered to five patients (combined with chemotherapy in four). Nine patients had not received reinduction chemotherapy Statistical analysis before BMT2.
The endpoints of survival analysis were survival (from transplantation until death, censored by the end of followProtocols at the time of BMT2 up), leukemia-free survival (LFS) (from transplantation until relapse or death, censored by the end of follow-up), Donors for BMT2 were the same as those for BMT1 in 55 patients. Nine sibling donors were replaced by eight other and remission duration (from transplantation until relapse censored by death or the end of follow-up). The probability siblings and one identical twin. Two syngeneic donors were substituted for two sibling donors. Thirty patients were in of survival was estimated by the method of Kaplan and Meier, 9 and the levels of statistical significance were calcuremission (CR) and 24 were not in remission (NR) ( tests. In two patients who relapsed after BMT2 and in 15 patients; seven liver damage, three heart damage, one renal damage, three infectious disease and one heart and received a third BMT, survival was censored at the time of the third BMT. liver disease. Preparative conditioning for BMT2 varied
Results
less than 1 year duration from BMT1 to BMT2 ( Figure 1a . Leukemia-free survival 6.5 months (median 0.9 months) after BMT2. Seven was 33% at 1 year, 28% at 2 years and 16% at 4 years. patients were alive without relapse between 9.5 and 38.6 Overall relapse rate was 52% at 2 years and 70% at 4 years months (median 26.3 months) after BMT2. Prognosis for (Figure 1b) .
33 cases who received BMT2 more than 1 year after BMT1 was compared. Fourteen relapsed between 1.7 and 42.9 months (median 10 months) and 10 died without relapse Time between BMT1 and relapse or BMT1 and BMT2 between 0.5 and 36.8 months (median 3.4 months) after Time from BMT1 to relapse or BMT1 to BMT2 were BMT2. Nine patients were alive without relapse betwen important prognostic factors for BMT2. When we com-12.3 and 36.8 months (median 23.5 months) after BMT2. pared the two groups by duration from BMT1 to relapse, survival, LFS and remission duration were worse with earlier relapse (Ͻ6 months) than later relapse (Ͼ6 months)
Differences in disease status at the time of BMT2 ( Figure 3 , Table 2 ). Comparison of time from BMT1 to BMT2 showed that shorter duration resulted in shorter surSurvival and LFS of 32 patients who were in remission vival after BMT2. Only one among 11 cases retransplanted (CR) at BMT2 (including one with chronic phase CML and within 6 months of BMT1 remained in remission for more one with MDS-RA) were compared with those of 32 than 6 months. LFS was significantly lower than that of 55 patients who were not in remission (NR) including four in patients retransplanted more than 6 months after BMT1.
blast crisis and one in accelerated phase of CML (Figure Similar results were observed when assessed by more or 1a). There was statistically significant LFS but not survival by Cox-Mantel and generalized Wilcoxon tests (Table 2) . Most relapses were observed within 24 months after BMT2 in both groups. The relapse rate of NR patients was higher (65% at 2 years) than that of CR patients (50% at 2 years), which was statistically significant (Figure 1b) . When LFS was assessed according to type of acute leukemia, ALL had a lower survival rate than ANLL ( Figure  2a ), caused by a higher relapse rate in ALL than ANLL (Figure 2b) .
Comparison of survival after BMT2 according to conditioning before BMT2
Because high-dose chemotherapy before BMT2 varied even in the same institute, we selected six regimens (CY, TBI, BU, Ara-C, Eto and Mel) and determined high-dose criteria to compare the survival rate. In order to analyze the relationship between prognosis of BMT2 and regimen intensity, we counted the number of regimens and compared LFS after BMT2 after the less intensive regimens (рtwo high-dose regimens) and the more intensive ones (Ͼtwo high-dose regimens). When early relapse rates within 3 months after BMT2 of both groups were compared, 2/28 relapses were observed in the more intensively treated group whereas 8/38 were seen in the less intensive one. These results did not reflect longer LFS in the former group, when compared by the numbers of survivors and by both Cox-Mantel and generalized Wilcoxon tests.
We also analyzed the effect of each high-dose regimen. the case in patients not receiving TBI. 
Therapy-related death
The most important factors which affected early survival were therapy-related toxicities, including side-effects of conditioning (RRT), infections, and acute GVHD. Fourteen patients died within 3 months of BMT2. Causes of death were RRT in seven, infection in three, GVHD in two and IP in two patients. In these patients, the median duration between BMT1 and BMT2 was 9.8 months, and the average number of high-dose therapies was 2.2. When patients 1/10 in later ones (P Ͻ 0.01).
Comparison of duration of remission after BMT2 by the ation at time of BMT2 (CR or NR), and type of disease (ALL or ANLL). Most of our cases with short intervals presence of graft-versus-host disease
between BMT1 and relapse or BMT2 relapsed early and To ascertain the effect of GVHD on post-BMT2 survival died of RRT. Similar results 7,8 have described LFS as being and relapse, we compared presence or absence of acute shorter among patients who relapsed within 6 months of GVHD. Twenty-three cases developed grades I to II acute their first transplant, because of a higher relapse rate and GVHD whereas 28 did not. Survival, LFS and CR duration RRT. Longer LFS was observed in those who received were compatible between groups. Only 39 cases were fol-BMT2 in disease remission. Because only a small number lowed for more than 100 days, and 18 developed limited of CML patients were included in our study, we could not or extended chronic GVHD. Relapse rate was significantly ascertain the difference in survival between acute leukemia lower in 18 patients with chronic GVHD than in 21 patients and CML, whereas Radich et al 8 have shown that LFS after without evidence of chronic GVHD (Figure 4) . Five trials BMT2 was higher in CML. Higher relapse rates and of removal of GVHD prophylaxis in those without GVHD reduced LFS were observed in ALL in our study. at BMT1 resulted in one with grade III acute GVHD folIn order to optimize pre-BMT regimens for high relapse lowed by generalized chronic GVHD, and one with fatal risk leukemias, we also analyzed the effects of high-dose grade IV acute GVHD. regimens before BMT2. When compared by life-table analysis, neither regimen selection nor regimen intensity influenced survival and relapse. These data indicate the difDiscussion ficulty in eliminating residual leukemia by chemotherapy alone. Similar results were shown by Barrett et al 5 who After decades of experience of allogeneic BMT, leukemia reported 90 cases of leukemia relapse after BMT treated relapse is the most prominent cause of death after BMT, with re-BMT. Thirteen cases were leukemia-free for and it is necessary to establish a strategy to prevent or to between 27 and 80 months. They suggested that improved treat this problem.
results might be achieved by further reducing preparative From previous reports concerning treatment of postregimen intensity, and by increasing graft-versus-leukemia BMT leukemia relapse, reinduction chemotherapy (CT), reactivity. Our results partially agree with these results with BMT2, IFN-␣, and donor leukocyte infusions have been regard to GVHD, indicating the effectiveness of postused, but none of these approaches are optimal. Although BMT immunotherapy. approximately 50% of AML or ALL patients achieve Several strategies have been reported recently 1,2 concernremission after standard induction CT, most patients finally ing prophylaxis and treatment of leukemia relapse after relapse and die of resistant leukemia. 12 The effects of IFN-BMT. After relapse, treatment of leukemia is very difficult ␣ resulted in 10-25% cytogenetic complete remission in but survival is very short (less than 6 months) without treatpatients with CML in CP. 4 Infusion of donor leukocytes ment. 3, 12 Reinduction chemotherapy for acute leukemia is was also effective, but acute GVHD and bone marrow aplaeffective, and up to a 70% remission rate has been reported sia were common complications. Long-term effects of both in late relapses resulting in relatively longer survival. 3 Even latter procedures have not yet been fully evaluated.
in those who were in remission, the rate of long survival Another approach is a second allogeneic BMT. The pur-(more than 2 years) is approximately 10%. Although better pose of our study was to analyze the effect of a second survival after post-BMT relapse has been observed in CML transplant for post-BMT relapse in Japan, and to establish cases who responded to treatment with interferon-␣, with the best way to accomplish the second transplant.
or without donor leukocyte transfusion, long survival and Factors affecting leukemia-free survival after BMT2 cure have still been uncommon. 4 These reports highlight were duration between BMT1 and relapse (or BMT2), situthe difficulties in treating leukemia relapse after BMT. The strategy to decrease relapse comprises three parts: prediction of high relapse risk 13 and reorganization of pre-BMT conditioning for this group, 14 prevention of relapse by reduction of invisible leukemia cells with induction of GVHD (GVL), and finally, prediction of minimal residual disease 15 and early treatment of MRD by biological response modifiers such as IFN␣, IL-2 and TNF. General Hospital, Division of Internal Medicine, Kamogawa,
